Azstarys FDA Approval History
Last updated by Judith Stewart, BPharm on March 10, 2021.
FDA Approved: Yes (First approved March 2, 2021)
Brand name: Azstarys
Generic name: dexmethylphenidate and serdexmethylphenidate
Dosage form: Capsules
Company: KemPharm, Inc.
Treatment for: Attention Deficit Hyperactivity Disorder (ADHD)
Azstarys (dexmethylphenidate and serdexmethylphenidate) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older.
- Azstarys contains serdexmethylphenidate, a prodrug of dexmethylphenidate, co-formulated with immediate-release dexmethylphenidate.
- The drug/prodrug combination is thought to provide an early onset of action and long duration of action without the spikes in dexmethylphenidate concentrations that may be associated with adverse events.
- Azstarys capsules are taken once daily with or without food.
- Common side effects include decreased appetite, insomnia, nausea, vomiting, dyspepsia, abdominal pain, decreased weight, anxiety, dizziness, irritability, affect lability, tachycardia, and increased blood pressure.
Development timeline for Azstarys
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
